Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11576616 | 0.81 | MAPT (0.58) | MAPTNOS1POLBMAOBCYP3A4 | |
| SCHEMBL1456660 | 0.80 | NOS1 (0.53) | MAPTNOS1POLBMAOBCYP3A4 | |
| SCHEMBL20110644 | 0.80 | MAPT (0.53) | MAPTNOS1POLBMAOBCYP3A4 | |
| SCHEMBL760017 | 0.80 | MAPT (0.53) | MAPTNOS1POLBMAOBCYP3A4 | |
| SCHEMBL1456967 | 0.74 | MAPT (0.50) | MAPTNOS1POLBMAOBCYP3A4 | |
| SCHEMBL11577937 | 0.74 | METAP2 (0.39) | MAPTNOS1LRRK2 | |
| SCHEMBL10179371 | 0.71 | ALDH1A1 (0.41) | MAPTNOS1POLBMAOBLMNA | |
| SCHEMBL29730539 | 0.70 | MAPT (0.57) | MAPTNOS1POLBMAOBCYP3A4 | |
| SCHEMBL1496173 | 0.70 | MAPT (0.57) | MAPTNOS1POLBMAOBCYP3A4 | |
| SCHEMBL27139257 | 0.70 | NOS1 (0.53) | MAPTNOS1POLBMAOBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368132-A1 | ROCK2 INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4377306-A1 | ROCK2 INHIBITORS AND USES THEREOF | President and Fellows of Harvard College (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118055926-A | ROCK2 inhibitors and uses thereof | 哈佛大学的校长及成员们 | 2024-05-17 | — | — | CN | disclosed |
| CN-117756805-A | Pteridinone derivatives as RSK inhibitors and their use | 华东师范大学 | 2024-03-26 | — | — | CN | disclosed |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2023009475-A1 | ROCK2 INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | WO | disclosed |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | ESCAPE Bio, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114450274-A | Indazoles and azaindazoles as LRRK2 inhibitors | 伊斯凯普生物公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3164509-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-10414750-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414750-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194162-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194162-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180265491-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3164509-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016004105-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368132-A1 | ROCK2 INHIBITORS AND USES THEREOF | ROCK2, ROCK1, RHOA | MAPT 1272/4885NOS1 79/4885POLB 4124/4885 |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | LRRK2, PARK7, GDI2 | MAPT 66/4885NOS1 3421/4885POLB 4324/4885 |
| US-10414750-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | MAPT 3093/4885NOS1 854/4885POLB 2723/4885 |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | MAPT 66/4885NOS1 3421/4885POLB 4324/4885 |
| US-20190194161-A1 | INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | MAPT 2977/4885NOS1 896/4885POLB 2745/4885 |
| US-20190194162-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | MAPT 3093/4885NOS1 854/4885POLB 2723/4885 |
| US-20180265491-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | MAPT 3093/4885NOS1 854/4885POLB 2723/4885 |
| US-20100298377-A1 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS | WEE1, PRMT1, ABL1 | MAPT 2039/4885NOS1 319/4885POLB 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.